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ABSTRACT
Introduction: Anti-vascular endothelial growth factor (VEGF) therapy has become the most commonly
used treatment for macular edema secondary to retinal vein occlusion (RVO). Although its superior
efficacy as compared to other interventions has been proven, there is a lack of evidence for relative
efficacy among anti-VEGF drugs.
Areas covered: This work systematically reviewed and compared the efficacy of intravitreal bevacizu-
mab, ranibizumab, and aflibercept for treating macular edema due to RVO. PubMed, EMBASE, and the
Cochrane Library were searched from their inception until October 2017. Eleven randomized controlled
trials (18 articles; 1830 adult patients) were identified. The proportion of patients who gained at least 15
letters in best-corrected visual acuity (BCVA), mean change from baseline in BCVA, and mean change
from baseline in central macular thickness (CMT) were reported and these efficacy outcomes at
6 months were analyzed in network meta-analysis.
Expert commentary: Apparently, bevacizumab, ranibizumab, and aflibercept were significantly super-
ior to sham injection in terms of BCVA improvement and CMT reduction and had good safety profiles.
However, there were no statistically significant differences in any outcomes among anti-VEGF drugs. In
selecting an anti-VEGF drug for individual patients, other factors including affordability, drug availabil-
ity, and patient characteristics should be considered.
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1. Introduction
Macular edema due to retinal vein occlusion (RVO) hold the
second rank of the most common type of retinal vascular
diseases after diabetic retinopathy [1,2]. Progressively blurry
vision in patients with RVO mainly results from macular
edema. Although branch retinal vein occlusion (BRVO) is the
most prevalent type (0.44%) compared to central retinal vein
occlusion (CRVO) (0.08%), significant vision loss caused by
macular edema secondary to CRVO is more frequent [2–4].
Apart from grid laser photocoagulation for BRVO treatment
and panretinal photocoagulation for both CRVO and BRVO
treatment, intravitreal corticosteroids have been used to
treat macular edema secondary to RVO but they are likely to
increase the risk of cataract progression and intraocular pres-
sure elevation [5–7]. Recently, anti-vascular endothelial growth
factor (VEGF) therapy has become the treatment of choice for
this ocular disorder. The efficacy and safety of anti-VEGF drugs
have been proven by randomized controlled trials (RCTs)
[1,8,9]. Ranibizumab and aflibercept have been licensed for
treating various retinal diseases and cost of these treatments is
tremendous, while bevacizumab has been used off-label as a
cheaper alternative. Limited evidence comparing the efficacy
of available anti-VEGF drugs also has an impact on decision-
making on prescribing and reimbursing a drug for patients
with RVO.
In Thailand, there was no pharmacotherapeutic agent for
treatment of macular edema secondary to RVO available in
benefits package for patients under the two major national
health insurance schemes, the Universal Coverage scheme
(UC) and the Social Security Scheme (SSS), which covers
approximately 92% of the country’s population [10]. Thus,
the patients need to pay out of pocket for both licensed
drugs and off-label bevacizumab. Evidence generation to
support the drug choice is crucial. A previous meta-analysis
of RCTs published until December 2011 [11] was used to
inform Thai policymakers to include bevacizumab into the
National List of Essential Medicines (NLEM) for neovascular
age-related macular degeneration (nAMD) and diabetic
macular edema (DME), but there was limited evidence to
compare efficacy outcomes between bevacizumab and
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ranibizumab in RVO patients. Ford and colleagues summar-
ized that anti-VEGF drugs and triamcinolone were effective
for these patients but they could not perform meta-analysis
due to lack of head-to-head trials [6]. More recent systema-
tic reviews and meta-analyses did not show relative efficacy
of individual anti-VEGF drug [5]. Another network meta-
analysis excluded bevacizumab which has been widely
used off-label in clinical practice, from the quantitative ana-
lysis [12]. Nevertheless, the SCORE2 study [13], the recent
RCT comparing the efficacy of bevacizumab to aflibercept,
was published and has not been included in any meta-
analysis.
Thus, this study aimed to review and compare relative efficacy
among anti-VEGF drugs for the treatment of macular edema
secondary to RVO by combining data from published RCTs.
2. Methods
This systematic review was conducted and reported in accor-
dance with the PRISMA guideline for network meta-analyses.
2.1. Search strategy
Study search was conducted on the following electronic data-
bases: PubMed, EMBASE (all via OVID), and the Cochrane Library
from their inception until 25 October 2017. Reference lists of
previous systematic reviews were also reviewed to identify addi-
tional eligible studies. Search terms referring to study population
that included those who were diagnosed with RVO (both BRVO
and CRVO) and terms relating to study interventions such as
bevacizumab, ranibizumab, aflibercept, and anti-VEGF agents
were included (Table S1, Supporting Information).
2.2. Selection of studies
Titles and abstracts of identified articles were screened and
selected by two independent reviewers. Full texts of selected
literature were retrieved and assessed against eligibility cri-
teria. The reasons for exclusion of studies were recorded
(Table S2, Supporting Information). Discrepancies between
the two reviewers were resolved by discussion.
2.3. Inclusion and exclusion criteria
In order to be included in this review, all studies had to
meet all of the following criteria:
(1) The study population consisted of patients diagnosed
with RVO. Both BRVO and CRVO were eligible.
(2) Interventions of interest were intravitreal bevacizumab
(IVB), intravitreal ranibizumab (IVR), and intravitreal afli-
bercept (IVA).
(3) Treatment comparisons were IVA, IVB, IVR, and sham.
(4) Outcomes were the proportion of patients gaining at
least 15 letters from baseline, mean change in best-
corrected visual acuity (BCVA) from baseline, and
mean change in central macular thickness (CMT) from
baseline.
(5) Studies were designed as RCTs.
Studies published in English were eligible for inclusion in
the review. Only studies that provided sufficient data of effi-
cacy outcome at baseline and month 6 and compared the
efficacy of the following interventions: 1.25 mg IVB, 0.5 mg
IVR, 2 mg IVA, and sham, were included for network meta-
analysis (NMA).
2.4. Data extraction
Authors, year of publication, baseline characteristics of
included studies, and outcomes of interest were indepen-
dently extracted by two reviewers. Disagreement between
the two reviewers was resolved by discussion to reach con-
sensus. We also contacted corresponding authors of the stu-
dies to request for information which was incomplete.
2.5. Outcomes of interest
Primary outcomes were (1) the proportion of patients who
gained at least 15 letters or 3 lines at 6 months, (2) improve-
ment in BCVA (letters), and (3) decrease in CMT (micrometers;
μm) from baseline to 6 months. In RCTs, visual acuity (VA) was
frequently quantified and reported as Early Treatment Diabetic
Retinopathy Study (ETDRS) letter score. When the Logarithm
of the Minimum Angle of Resolution (logMAR) or Snellen chart
scores was used to measure VA outcome, the score was con-
verted to approximate ETDRS letter scores using the method
proposed by Gregori et al. [14] in order to be included in
quantitative analysis.
logMAR = −1 × log (Snellen fraction)
Approximate ETDRS letter scores = 85 + 50 × log (Snellen
fraction)
2.6. Risk of bias assessment
Two authors independently assessed and reported methodo-
logical risk of bias of included studies using the Risk of Bias 2.0
(RoB2.0) tool. This is a revised tool of the Cochrane collabora-
tion proposed by Higgins et al. [15] for assessing randomized
trials according to the following domains: bias arising from the
randomization process, bias due to deviations from intended
interventions, bias due to missing outcome data, bias in mea-
surement of the outcome, bias in selection of the reported
result, and overall bias. Any disagreements on the risk of bias
evaluation are resolved by consensus.
2.7. Statistical analysis
Results for patients gaining at least 15 letters were presented
as count and percentage. BCVA and CMT were reported as
mean changes from baseline and standard deviation (SD) or
95% confidence interval (CI). Risk ratio (RR) for gaining ≥15
letters and mean differences (MD) between treatment groups
in BCVA and CMT changes from baseline along with 95% CI
were estimated for individual trial and pooled across studies. If
SDs of MDs were not reported, we computed SDs from avail-
able standard error (SE), 95%CI or p values. Additionally, we
contacted authors for providing missing SDs when the infor-
mation of uncertainty was not reported.
904 S. SANGROONGRUANGSRI ET AL.
An NMA was conducted on data that were explicitly reported
in each trial. Mixed treatment effects were presented as RRs or
MDs against sham injection as a common comparator. A relative
treatment effect was defined as significant if 95% CIs of RRs and
MDs did not include one and zero, respectively.
Consistency was assessed by fitting both the consistency and
inconsistency models. We tested the consistency assumption
(discrepancies between the direct and indirect evidence of the
efficacy of anti-VEGF drugs and sham intervention) by the global
Wald test for the overall inconsistency and node-splitting ana-
lyses as a local test on loop inconsistency [16]. A consistent
model was employed when an inconsistent model was not sig-
nificantly indicated by p values of global test and node split
model was more than 0.05 (failed to reject a common hetero-
geneity estimate at the overall level of each treatment andwithin
each loop). Publication bias was assessed using funnel plot.
Sensitivity analyses were conducted to examine the robustness
of the NMA. Impact of excluding RCTs conducted in patients with
macular edema due to BRVO was assessed. We determined
relative rankings of treatments to identify superiority among
treatments as well as the percentage probability of being the
most efficacious treatment at 6 months for each outcome.
STATA software (version 14.2, StataCorp, College Station,
TX, USA) was used to perform NMA and ranking efficacy of
interventions. A two-sided test with p value less than 0.05 was
considered as statistically significant.
3. Results
3.1. Search results
Figure 1 illustrates the study flow of this systematic review. We
identified 117, 106, and 178 publications from PubMed,
EMBASE, and Cochrane Library, respectively. Reasons for exclu-
sion were explained in Table S2 (Supporting Information).
Among 11 eligible studies, 5 RCTs (12 publications) were
separately published at different follow-up periods. Three
RCTs were excluded from quantitative synthesis: a study con-
ducted by Khan and colleagues [17] comparing efficacy of
1.25 mg of IVB starting at month 0 (immediate) and month 4
(deferred), a study conducted by Moradian et al. [18] which
followed patients for only 3 months, and a study by Lucatto
et al. [19] that reported outcomes as graphs without specific
values.
Figure 1. Study flow diagram.
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3.2. Study characteristics
Characteristics of included studies are summarized in Table 1
and Table S3 (Supporting Information). The length of follow-
up varied from 3 to 24 months. Of 11 studies, a trial by Khan
and colleagues [17] was described as open label and com-
pared the same intervention (immediate IVB and deferred IVB).
Five studies (45.5%) were single-center RCTs. There were five
industry-funded RCTs [20–30] and the SCORE2 trial [13]
received donated investigational drugs from pharmaceutical
companies.
Five RCTs [13,23,28,31,32] described sample size determina-
tion and achieved the required sample sizes for the functional
outcomes (i.e. BCVA letter gain and the proportion of patients
gaining ≥15 letters).
Most included RCTs were likely to have methodological
similarity. For example, they enrolled treatment-naive patients
or patients who received prior anti-VEGF therapy more than
2–3 months. Retinal thickness at baseline had to be at least 250
or 300 μm in order to be eligible for participating in the studies.
The optical coherence tomography (OCT) machines (manufac-
turers) used to measure CMT were varied across studies: Cirrus
HD-OCT (Carl Zeiss Meditec Inc., Dublin, CA, USA) [13,17,31,32],
Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany)
[13,19], Stratus OCT (Carl Zeiss Meditec Inc., Dublin, CA, USA
and Carl Zeiss Meditec, Jena, Germany) [18,20,23,25,28,30], and
3D-OCT 1000 (Topcon Corporation, Tokyo, Japan) [20]. Using
different OCT machines might result in slight difference in
measured CMT values. Approximately 73% of studies reported
mean time from RVO diagnosis and they included only patients
who were diagnosed with RVO within 12 months prior to
enrollment. Most studies used ETDRS chart which was com-
monly used in clinical research studies except three studies
[17–19] that measured BCVA by using the Snellen chart. In
each trial, patients’ baseline characteristics, including age, base-
line BCVA, and baseline CMT, were similar between the compar-
ison groups. However, patient characteristics at baseline were
imbalanced across all trials in terms of time from RVO diagnosis
to treatment, BCVA, and CMT.
In most trials, patients received the monthly injection of the
drugs for the first 5 or 6 months [13,19,21–30] (for 3 months in
ROCC [20]), then followed by monthly pro re nata (PRN or as
needed) regimen in the extension phase. MARVEL [31] applied
the monthly PRN regimen throughout the study period. The
Studies by Epstein et al. [32,33] and Moradian et al. [18]
treated patients every 6 weeks and the latter study gave
only two injections of IVB or sham at week 0 and 6. In
GALILEO [21–23] and COPERNICUS [26–28], patients were trea-
ted with IVA or sham every 2 months as needed after week 52
in both IVA and sham groups.
Almost all included RCTs had above 80% of patients who
completed 6 months of the studies in each treatment arm.
There were higher proportions of patients who discontinued
the study in sham group compared to IVA group in GALILEO
[23] (90.6% versus 78.9%) and COPERNICUS [28], (95.7% versus
81.1%). The main reasons included adverse events and lack of
efficacy. Analyses of the full analysis set of all randomized
patients and sensitivity analyses for the primary end point
were conducted in both trials.
3.3. Risk of bias assessment
Most RCTs conducted in patients with CRVO had the low risk
of bias for all domains, while overall bias for most studies
conducted in patients with BRVO were some concerns and
high risk of bias (Table S4, Supporting Information). The study
conducted by Khan et al. [17] had a high risk of randomization
process and measurement of the outcome bias due to an
unblinded design.
3.4. Efficacy outcomes
These studies show that the anti-VEGF drugs had a signifi-
cantly greater improvement in BCVA and reduction of CMT
compared to the sham group in both fixed (every 4 or
6 weeks) and monthly PRN treatment regimens (Table 2).
The improvement of functional and anatomical outcomes
could be seen as early as 4 weeks after the first injection.
The achieved improvements in the outcomes of interest
were maintained after the primary outcome measurement.
In COPERNICUS [26–28], IVA was significantly superior to
sham injection in terms of visual function outcome until
week 100, while CMT reduction between groups was simi-
lar after week 24. Nevertheless, there was no difference in
all outcomes of interest among IVA, IVB, and IVR. PRN
dosing schedule was, generally, sufficient to maintain the
improved outcomes. The studies of Khan et al. [17] and
Epstein et al. [32,33] were suggested that prompt IVB
treatment had greater efficacy and needed lesser numbers
of the drug injection as well as rescue laser treatment
compared to delayed treatment. A small study (n = 35)
[19] examining functional and anatomic outcomes as sec-
ondary end point found that improvement of BCVA in IVB
group was significantly better than intravitreal triamcino-
lone acetate (IVTA) and sham groups only at month 1,
while there was no statistically significant difference in
CMT reduction throughout the study period.
3.5. Network meta-analysis
The network of treatment comparisons for the proportion of
patients gaining at least 15 ETDRS letters, mean change from
baseline to month 6 in BCVA, and mean change from baseline to
month 6 in CMT are presented in Figure 2. Treatment regimens
within the first 6 months of the RCTs [13,23,25,28,30–32] were,
generally, similar among the included studies.
All analyses met the consistency assumption confirming
the agreement between direct and indirect sources of evi-
dence (Table S6, Supporting Information). The treatment effect
estimates derived from NMA were reported in Table 3 and
Figure S2 (Supporting Information).
The proportion of patients who gained 15 and more letters
within 6 months were significantly higher for aflibercept (RR
2.98 (95% CI 2.15–4.12)), bevacizumab (2.69 (2.01–3.59)), and
ranibizumab (2.45 (1.93–3.11)) when compared to sham injec-
tion. The statistically significant increase in BCVA letter gained
from baseline was found for aflibercept (+16.74 (12.62–20.87)),
bevacizumab (+14.87 (9.65–20.09)), and ranibizumab (+13.42
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(9.62–17.21)) when compared to sham injection. In terms of
CMT, anti-VEGF groups were superior in CMT reduction com-
pared to sham group: aflibercept (MD −325.97 (95% CI
−512.95 to −139.00)), bevacizumab (−346.49 (−548.01 to
−144.97)), and ranibizumab (−412.36 (−575.86 to −248.85)).
However, there was no significant difference in all efficacy
outcomes between the anti-VEGF drugs (Table 3 and
Figure S2).
The probabilities of being the most efficacious treatment
based on the proportion of patients gaining ≥15 letters, change
in BCVA, and change in CMTwere aflibercept (80.1%), aflibercept
(73.1%), and ranibizumab (63.6%), respectively (Figures 3 and 4).
3.6. Sensitivity analyses
The impact on the results was investigated when only data from
the studies in CRVO patients were included. Treatment effect sizes
in patients withmacular edema secondary to CRVOwere summar-
ized in Table 4. There was a limited impact of excluding trials
conducted in patients with BRVO [30,31] from the network of
results. Anti-VEGF drugs remained significantly superior to sham
for all outcomes. In comparison with the main analysis, the mag-
nitude of differences in improvement of functional outcomes
between the active drugs versus sham was slightly increased,
while the advantage in CMT reduction of these anti-VEGF drugs
versus sham was slightly reduced. Besides, the best treatment for
each outcome of interest remained unchanged. Aflibercept was
still the most efficacious drug in terms of the proportion of
patients gaining 15 andmore letters but its percentage probability
decreased from 80.1% to 62.1%, compared with 27.4% for ranibi-
zumab and 10.5% for bevacizumab. Similarly, the probability of
aflibercept being the best treatment to improve letter gained was
also reduced from 73.1% to 50.2%, compared with 39.1% for
bevacizumab and 10.7% for ranibizumab.
4. Discussion
4.1. Principal findings
The NMA results showed that anti-VEGF therapy was the
effective treatment to improve vision and reduce macular
edema in patients with both CRVO and BRVO. IVA 2 mg, IVB
1.25 mg, and IVR 0.5 mg were superior to sham treatment in
all outcomes of interest. Although IVA was ranked first in
terms of improving BCVA letter gained and IVR was the best
drug based on CMT reduction, there was no statistically sig-
nificant difference in improving mean change from baseline in
BCVA letter score, reducing CMT, and the proportion of
patients with BCVA gain of at least 15 ETDRS letters among
all anti-VEGF drugs.
Qian and colleagues [5] pooled data from 11 RCTs and
directly compared the efficacy of intravitreal anti-VEGF
therapy to intravitreal triamcinolone acetate/dexametha-
sone or laser therapy. They found that anti-VEGF treatment
was more efficacious than the corticosteroids or laser ther-
apy. The significant differences in improving BCVA and
reducing CMT between groups could be seen as early as
3 and 6 months in eyes with BRVO and CRVO, respectively.
These results suggested a possible impact of venous
occlusion location on the efficacy of anti-VEGF therapy,
showing that the treatment might be more effective in
BRVO patients in terms of anatomical changes. A previous
NMA [12] investigated efficacy of treatments licensed for
macular edema secondary to RVO (i.e. IVR 0.5 mg monthly
PRN, IVA 2 mg monthly, prompt laser photocoagulation,
dexamethasone 0.7 mg implant, and a combination of IVR
0.5 mg monthly PRN and laser photocoagulation) by ana-
lyzing data from eight RCTs which were published until
August 2014. Prior to conducting NMA, data of an indivi-
dual patient with BRVO in a treatment group were
matched to patients with BRVO in the comparison group
on baseline BCVA and duration of disease to account for
heterogeneity among the anti-VEGF trials. This study
reported that IVR and IVA monotherapy were ranked first
based on BCVA letter gained and the proportion of BRVO
patients gaining ≥15 letters, respectively, and the differ-
ence in efficacy of IVR against IVA was not statistically
significant (letter gained +1.4 (95% credible interval −5.2
to +8.5) letters and odds ratio of patients gaining at least
15 letters 1.06 (95% credible interval 0.16–8.94).
Braithwaite and colleagues systematically reviewed RCTs
which were published until October 2013 and compared
efficacy and safety of the anti-VEGF therapy to sham treat-
ment in patients with CRVO [34]. The results derived from
six RCTs (n = 937) were consistent with our findings that
patients treated with anti-VEGF drugs had better visual
improvement than those treated with sham. Pooled esti-
mates from high-quality evidence [20,23,25,28,32,35] for
BCVA gain of at least 15 letters and mean change in
BCVA from baseline to 6 months between anti-VEGF-trea-
ted and sham groups were RR 2.71 (95% CI 2.10–3.49) and
MD 15.23 letters (95% CI 11.57–18.89). Based on moderate-
quality evidence (three RCTs; n = 481), anti-VEGF treat-
ments decreased CMT at a higher degree than sham treat-
ment with a mean difference in mean change in CMT from
baseline to 6 months was −267.4 μm (95% CI −211.4 to
−323.4). At that time, there were no head-to-head RCTs
comparing efficacy between different anti-VEGF drugs to
be included in this meta-analysis [34].
Baseline BCVA and CMT, duration of RVO, subtypes of RVO,
the degree of severity and macula involvement, different OCT
devices, and the total number of injections might have an
impact on treatment outcomes across studies [5,12,13,19,32]
as well as the required re-injection of the drugs during the
PRN regimen. An initial CMT might affect the mean decrease
in CMT in each treatment group. A study suggested that a
thicker subfoveal choroidal thickness and a poorer BCVA at
baseline would be short-term positive predictors for visual
improvement following anti-VEGF therapy in patients with
BRVO [36]. Besides, the prognosis of RVO in ischemic form
(determined by the extent of retinal capillary non-perfusion
in fluorescein angiography image) and existing of relative
afferent pupillary defect is extremely poor and worsens visual
outcomes. Lucatto et al. [19] found the poor responses in
functional and anatomic outcomes which might be associated
with small sample size and poorer baseline BCVA and CMT
than other studies. In SCORE2, researchers reported that
imbalanced time from diagnosis of RVO to receiving treatment
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between IVA and IVB groups (8 versus 5 months) did not alter
the primary results after adjusting with this factor in the
secondary analysis. Our review found the lower levels of CMT
at baseline in trials in patients with BRVO and a wide range of
time from RVO diagnosis to randomization (1–8 months). A
sensitivity analysis was conducted by including only data from
Figure 2. Network geometry for efficacy outcomes at 6 months. (Numbers located next to the lines refer to the number of studies for direct comparisons.
Abbreviations: IVB, bevacizumab; IVR, ranibizumab; IVA, aflibercept.).
Table 3. Results of network meta-analyses of efficacy outcomes (A to C) for all treatments relative to each other under the consistency model.
Comparators Sham Ranibizumab Bevacizumab Aflibercept
A) Proportion of patients who gained ≥15 ETDRS letters: risk ratios (95% CIs)§
Sham – 2.45 (1.93,3.11) 2.69 (2.01,3.59) 2.98 (2.15,4.12)
Ranibizumab 0.41 (0.32,0.52) – 1.10 (0.82,1.46) 1.21 (0.89,1.65)
Bevacizumab 0.37 (0.28,0.50) 0.91 (0.68,1.22) – 1.11 (0.92,1.34)
Aflibercept 0.34 (0.24,0.47) 0.82 (0.61,1.12) 0.90 (0.75,1.09) –
B) Change in best-corrected visual acuity from baseline: mean differences (95% CIs)‡
Sham – 13.42 (9.62,17.21) 14.87 (9.65,20.09) 16.74 (12.62,20.87)
Ranibizumab −13.42 (−17.21,−9.62) – 1.46 (−4.22,7.13) 3.33 (−1.90,8.55)
Bevacizumab −14.87 (−20.09,−9.65) −1.46 (−7.13,4.22) – 1.87 (−3.03,6.77)
Aflibercept −16.74 (−20.87,−12.62) −3.33 (−8.55,1.90) −1.87 (−6.77,3.03) –
C) Change from baseline in central macular thickness: mean differences (95% CIs)‡
Sham – −412.36
(−575.86,−248.85)
−346.49
(−548.01,−144.97)
−325.97
(−512.95,−139.00)
Ranibizumab 412.36
(248.85,575.86)
– 65.86
(−153.58,285.31)
86.38
(−148.42,321.18)
Bevacizumab 346.49
(144.97,548.01)
−65.86
(−285.31,153.58)
– 20.52
(−198.33,239.36)
Aflibercept 325.97
(139.00,512.95)
−86.38
(−321.18,148.42)
−20.52
(−239.36,198.33)
–
Effect of an intervention in row was compared to effect of an intervention in column. §Risk ratio (RR) > 1 favors the treatment along top and RR < 1 favors the
comparator in left-hand column. ‡Mean difference (MD) > 0 favors the treatment along top and MD < 0 favors the comparator in left-hand column. Abbreviations:
CIs, confidence intervals.
Figure 3. Percentage probability of each treatment being ranked first by outcome measure. (Abbreviations: ETDRS, early treatment diabetic retinopathy study; BCVA,
best-corrected visual acuity; CMT, central macular thickness.).
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RCTs in patients with CRVO. This analysis showed a limited
impact on the results derived from the primary NMA of RCTs
conducted in patients with CRVO or BRVO. The direction of
results remained unchanged but the magnitude of the CMT
reduction between anti-VEGF drugs and sham treatment was
slightly decreased. On the contrary, we found greater BCVA
improvement in patients with CRVO.
4.2. Strengths and limitations
This study included most recent published RCTs including
head-to-head RCTs. Our analysis had transparent design and
no discrepancy between the direct and indirect treatment
evidence. However, the limitations of the study are needed
to be addressed. First, this review did not include unpublished
data. However, we could not retrieve additional unpublished
data suggested by the previous systematic reviews and meta-
analyses [5,12]. Second, we did not address variation across
RCTs in certain key eligibility criteria. Although study popula-
tions among included RCTs were different, all studies showed
the benefits of anti-VEGF therapy over sham treatment. Due to
limited data and numbers of included trials, we did not per-
form matching on confounding factors using patient-level
data or adjustment for these factors using meta-regression.
Therefore, caution should be made when interpreting the
results. Third, most studies had the short period of follow-up
for this potentially chronic disease. Moreover, the quantitative
analysis did not include the outcomes after the 6-month
follow-up. We perceived that pooling data from the trials
with the similar regimen (fixed dosing schedule every
4–6 weeks for the first six months) would provide more valid
results. Moreover, availability of outcomes at 6 months was
better than data reported at the longer follow-up period.
Finally, the major source of uncertainty of our findings was
likely to be limited evidence with small sample sizes. Missing
data from high dropout rates and different attrition rates
between treatment groups might also have an impact on
estimates of the treatment effect. However, their results
remained consistent after performing several methods such
as intention-to-treat analysis, sensitivity analysis, and imputa-
tion of missing data.
5. Conclusion
This study and the previous meta-analyses [5,12,34] proved
that anti-VEGF therapy possesses clinical benefit for treating
patients with macular edema due to RVO over sham, corticos-
teroids, laser therapy, and good short-term safety profile.
Figure 4. Probability that each treatment being ranked the first, second, third, and forth most effective for efficacy outcomes.
Table 4. Results of sensitivity analysis of efficacy outcomes in patients with macular edema secondary to central retinal vein occlusion.
Treatment
Proportion of patients gaining ≥15
letters: risk ratio (95%CI)
Change form baseline in BCVA: Mean
difference (95% CI)
Change form baseline in CMT: Mean
difference (95% CI)
Aflibercept versus sham 3.26 (2.32–4.59) 17.57 (13.17–21.97) −308.68 (−538.77 to −78.59)
Bevacizumab versus sham 3.00 (2.08–4.32) 17.05 (10.69–23.40) −295.95 (−582.60 to −9.29)
Ranibizumab versus sham 2.82 (1.85–4.29) 13.93 (8.28–19.58) −400.19 (−664.11 to −136.28)
Bevacizumab versus aflibercept 0.92 (0.78–1.08) −0.52 (−5.95 to 4.90) 12.73 (−269.22 to 294.68)
Ranibizumab versus aflibercept 0.86 (0.50–1.49) −3.64 (−10.81 to 3.53) −91.52 (−441.68 to 258.65)
Ranibizumab versus bevacizumab 0.94 (0.54–1.64) −3.12 (−11.62 to 5.39) −104.25 (−494.03 to 285.54)
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Available evidence could not identify the significant difference
in BCVA improvement and CMT reduction among IVA, IVB, and
IVR at short-term treatment.
6. Expert commentary
The findings from this systematic review and NMA might be
used as evidence to support decision-making on listing an
anti-VEGF drug into the NLEM for RVO treatment and selecting
the drug for patients with this retinal disease. While the num-
ber of Thai citizen with the UC or SSS who get access to IVB
treatment for treating their poor vision due to nAMD or DME
has been increased after the inclusion of the drug into the
NLEM, these beneficiaries with RVO are still required to pay
out of pocket for receiving any anti-VEGF drugs. To select an
appropriate anti-VEGF drug for an individual patient, there
were several factors that should be taken into consideration.
One of the major concerns over the use of bevacizumab for
ocular treatment is feasibility to properly re-package this anti-
cancer drug into small doses for intravitreal injection (e.g.
infrastructure, well-trained staff). Post-injection endophthalmi-
tis outbreaks were reported to be linked to microbial contam-
ination during the compounding procedure [37–39]. In
Thailand, the staff of the pharmacy department of a hospital
are usually responsible for the bulk re-packaging process of
bevacizumab which one vial of the drug can be divided into
20–70 doses and studies [40–42] showed the low rate of
endophthalmitis in Thai patients treated with intravitreal injec-
tion of anti-VEGF drugs. Another concern is the legal issue for
this off-label use in some countries [43,44]. Regardless of these
concerns, IVB is likely to be a favorable choice with equivalent
efficacy to IVA and IVR in RVO treatment at a much lower cost
per injection (Cost per injection of IVA, IVR, and IVB were
approximately 45,047, 45,482, and 750–1500 Thai baht,
respectively). Additionally, the increased risk of anti-VEGF-
associated thromboembolic events in bevacizumab group
was revealed in a cancer trial [45]; however, rates of this
serious adverse events found to be low in studies examining
risks of IVB in patients with retinal diseases [46]. Clinicians may
consider prescribing aflibercept or ranibizumab, the licensed
drugs for macular edema secondary to RVO, for patients who
experienced a recent stroke or myocardial infarction or have a
high risk of cardiovascular events. Moreover, the improved
VEGF-binding affinity of aflibercept [47] allows longer treat-
ment interval compared with monthly IVB and IVR [48]. As a
result, it can reduce the burden from frequent injections and
risk of procedure-related ocular adverse events in aflibercept
maintenance treatment.
Scatter photocoagulation has been added in the treatment
of RVO to reduce the burden of intravitreal anti-VEGF injec-
tions due to retinal ischemia and the high VEGF levels.
However, some studies including the RELATE study revealed
that adding laser did not result in the better visual and anato-
mical outcomes or reduce the need for frequent anti-VEGF
injections [49–51]. In terms of the treatment regimen, the
anti-VEGF therapy was frequently initiated with monthly
scheduled injections for six doses, and then the monthly as-
needed regimen was usually applied to maintain an optimum
level of visual function and macular thickness. Irreversible
retinal damage and limited efficacy of the drugs might be
caused by fewer injections due to a PRN treatment regimen
or delayed treatment [17,30–33]. Thus, it highlights the impor-
tance of immediate initiation of treatment and fixed monthly
dosing schedule at the early phase of treatment in order to
obtain better treatment outcomes and reduced overall num-
bers of the drug injections and rescue laser treatment during a
course of treatment. Efficacy of IVB given every 6 instead of
4 weeks was proven in one study [32]. This injection interval
would be advantageous in terms of mitigating treatment and
financial burden from drug injections and clinical visits as well
as reducing the risk of procedure-related ocular adverse
events.
Generalization of our results should be done with caution.
Findings from this study could not suggest the benefit of anti-
VEGF drugs in patients with time from RVO diagnosis longer
than 12 months. Additionally, most trials had high adherence
rates and strict eligibility criteria. As a result, the findings
might not reflect the efficacy of anti-VEGF drugs in real-
world practice.
7. Five-year view
Access to necessary treatment in a timely manner is crucial to
preserve vision of RVO patients. Among available treatment
options for treatment of macular edema associated with RVO,
repeated intravitreal anti-VEGF treatment has become first-line
therapy because of its efficacy and favorable safety profile.
According to the increase in people with non-communicable
diseases and population aging, the number of these patients
and the utilization of these drugs are expected to increase.
Current evidence demonstrated that the three anti-VEGF
drugs are likely to have similar clinical effects. Regarding
economic impact, IVR and IVA were considerably more costly
than IVB. The use of unlicensed IVB would result in substantial
cost savings to patients as well as public payers. Repeated
injections and reassessment of treatment with these drugs
have also placed burden on patients and health-care systems.
Therefore, determining relative efficacy of the as-needed sche-
dule as well as extended treatment interval during the main-
tenance phase has become an interest research area.
Novel anti-VEGF drugs and long-duration therapies will
affect the future use of the currently available drugs. There
are new VEGF inhibitors, biosimilars, and drug delivery sys-
tems for treating retinal vascular diseases in the pipeline.
Conbercept is a new approved anti-VEGF drug for treating
nAMD which is currently available only in China [52,53].
Conbercept can inhibit all VEGF isoforms and placenta growth
factor and has the longer half-life (7 days) than the other anti-
VEGF drugs which allows as-needed dosing regimen [54].
Trials and marketing plan in other countries for conbercept
are in the stage of planning. Brolucizumab is a humanized
single-chain antibody fragment with high binding affinity. The
phase 3 trials comparing brolucizumab to aflibercept in nAMD
patients demonstrated non-inferiority in mean BCVA gain and
safety profile between both drugs, and efficacy of brolucizu-
mab could be maintained with 12-week dosing intervals after
the loading phase through week 48 [52,53]. The biosimilar
versions of ranibizumab (PF582) and bevacizumab (BCD021)
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have undergone clinical studies [54]. The product launch will
depend on the patent expiry dates of their original drugs and
marketing plans. These agents would be more affordable
treatment options for patients with retinal diseases. Long-act-
ing anti-VEGF delivery systems for reducing the burden of the
frequent injections are still in development such as a sustained
release depot formulation of IVB which can be administered
every 4–6 months [54]. Another example is a refillable ranibi-
zumab port delivery system (RPDS). RPDS is implanted
beneath the conjunctiva and can be refilled as needed. This
reservoir can deliver ranibizumab at the therapeutic concen-
trations to vitreous for the extended duration [52].
There are several issues that are worth to be investigated
further. Studies comparing efficacy and safety of different anti-
VEGF drugs in patients who did not meet eligible criteria of
previous RCTs should be conducted. Further trials with larger
sample sizes would allow us to perform subgroup analyses
with sufficient statistical power and account for heterogeneity
in baseline factors that influence clinical outcomes. Sufficient
data on outcomes measured over longer periods of follow-up
would be beneficial to suggest sustained efficacy of the drugs.
Finally, effectiveness and safety profile of anti-VEGF agents in
real-life settings may be used as evidence to supplement
findings from RCTs which had limited generalizability.
Key issues
● Retinal vein occlusion (RVO) is one of the leading causes of
irreversible and profound loss of vision.
● Anti-vascular endothelial growth factor (VEGF) drugs have
become the most commonly used intervention to preserve
and restore the sight of these patients.
● Previous studies could not conduct network meta-analysis
to determine the most efficacious anti-VEGF drug for treat-
ing this condition due to limited evidence.
● The network meta-analysis revealed that all anti-VEGF drugs
have superior efficacy compared to sham treatment.
● There was no statistically significant difference in best-cor-
rected visual acuity (BCVA) improvement and central macu-
lar thickness (CMT) reduction among bevacizumab,
ranibizumab, and aflibercept at 6 months.
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